<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p165" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_165{left:35px;bottom:24px;letter-spacing:-0.34px;word-spacing:0.13px;}
#t2_165{left:306px;bottom:30px;}
#t3_165{left:313px;bottom:24px;letter-spacing:0.16px;}
#t4_165{left:346px;bottom:30px;}
#t5_165{left:351px;bottom:24px;letter-spacing:-0.16px;word-spacing:-0.22px;}
#t6_165{left:517px;bottom:30px;}
#t7_165{left:524px;bottom:24px;letter-spacing:-0.28px;word-spacing:-0.09px;}
#t8_165{left:288px;bottom:860px;letter-spacing:0.11px;word-spacing:-0.55px;}
#t9_165{left:288px;bottom:829px;letter-spacing:0.27px;word-spacing:-0.69px;}
#ta_165{left:1115px;bottom:27px;letter-spacing:0.23px;}
#tb_165{left:35px;bottom:777px;letter-spacing:0.24px;word-spacing:-0.05px;}
#tc_165{left:242px;bottom:785px;letter-spacing:0.1px;}
#td_165{left:287px;bottom:777px;letter-spacing:0.1px;word-spacing:0.09px;}
#te_165{left:35px;bottom:754px;letter-spacing:0.03px;word-spacing:0.16px;}
#tf_165{left:35px;bottom:731px;letter-spacing:0.09px;word-spacing:0.09px;}
#tg_165{left:35px;bottom:707px;letter-spacing:0.16px;word-spacing:0.03px;}
#th_165{left:210px;bottom:715px;}
#ti_165{left:255px;bottom:707px;letter-spacing:0.08px;word-spacing:0.1px;}
#tj_165{left:436px;bottom:715px;letter-spacing:-0.01px;}
#tk_165{left:460px;bottom:707px;letter-spacing:-0.02px;word-spacing:0.22px;}
#tl_165{left:35px;bottom:684px;letter-spacing:0.07px;word-spacing:0.12px;}
#tm_165{left:35px;bottom:661px;letter-spacing:0.03px;word-spacing:0.15px;}
#tn_165{left:35px;bottom:638px;letter-spacing:0.05px;word-spacing:-0.82px;}
#to_165{left:35px;bottom:614px;letter-spacing:0.09px;word-spacing:0.1px;}
#tp_165{left:35px;bottom:591px;letter-spacing:0.08px;word-spacing:0.11px;}
#tq_165{left:35px;bottom:568px;letter-spacing:0.13px;word-spacing:0.05px;}
#tr_165{left:35px;bottom:545px;letter-spacing:-0.02px;word-spacing:0.21px;}
#ts_165{left:270px;bottom:552px;}
#tt_165{left:315px;bottom:545px;letter-spacing:-0.02px;word-spacing:0.21px;}
#tu_165{left:35px;bottom:522px;letter-spacing:0.11px;word-spacing:0.07px;}
#tv_165{left:35px;bottom:498px;letter-spacing:0.05px;word-spacing:0.14px;}
#tw_165{left:282px;bottom:506px;}
#tx_165{left:328px;bottom:498px;letter-spacing:0.03px;word-spacing:0.15px;}
#ty_165{left:35px;bottom:475px;letter-spacing:0.16px;word-spacing:0.03px;}
#tz_165{left:150px;bottom:475px;letter-spacing:0.19px;}
#t10_165{left:532px;bottom:475px;letter-spacing:0.17px;word-spacing:0.01px;}
#t11_165{left:35px;bottom:452px;letter-spacing:0.02px;word-spacing:-0.93px;}
#t12_165{left:35px;bottom:430px;letter-spacing:0.06px;word-spacing:0.13px;}
#t13_165{left:35px;bottom:407px;letter-spacing:0.11px;word-spacing:0.08px;}
#t14_165{left:35px;bottom:366px;letter-spacing:0.02px;word-spacing:0.17px;}
#t15_165{left:35px;bottom:343px;letter-spacing:0.16px;word-spacing:0.03px;}
#t16_165{left:167px;bottom:351px;}
#t17_165{left:213px;bottom:343px;letter-spacing:0.18px;word-spacing:0.01px;}
#t18_165{left:35px;bottom:320px;letter-spacing:0.09px;word-spacing:0.1px;}
#t19_165{left:526px;bottom:327px;letter-spacing:0.12px;}
#t1a_165{left:35px;bottom:297px;letter-spacing:0.03px;word-spacing:-0.7px;}
#t1b_165{left:35px;bottom:273px;letter-spacing:0.09px;word-spacing:0.09px;}
#t1c_165{left:111px;bottom:281px;letter-spacing:-0.05px;}
#t1d_165{left:197px;bottom:273px;letter-spacing:-0.03px;word-spacing:-0.49px;}
#t1e_165{left:35px;bottom:250px;letter-spacing:-0.04px;word-spacing:0.22px;}
#t1f_165{left:380px;bottom:258px;letter-spacing:0.12px;}
#t1g_165{left:447px;bottom:250px;letter-spacing:-0.03px;word-spacing:0.22px;}
#t1h_165{left:35px;bottom:227px;letter-spacing:0.12px;word-spacing:-0.81px;}
#t1i_165{left:537px;bottom:235px;letter-spacing:-0.01px;}
#t1j_165{left:560px;bottom:227px;letter-spacing:0.45px;}
#t1k_165{left:35px;bottom:204px;letter-spacing:0.07px;word-spacing:0.12px;}
#t1l_165{left:35px;bottom:181px;letter-spacing:0.07px;word-spacing:0.11px;}
#t1m_165{left:35px;bottom:157px;letter-spacing:0.17px;word-spacing:0.02px;}
#t1n_165{left:35px;bottom:134px;letter-spacing:0.02px;word-spacing:-0.76px;}
#t1o_165{left:233px;bottom:142px;letter-spacing:0.1px;}
#t1p_165{left:277px;bottom:134px;letter-spacing:0.05px;word-spacing:-0.48px;}
#t1q_165{left:35px;bottom:111px;letter-spacing:0.06px;word-spacing:0.13px;}
#t1r_165{left:618px;bottom:777px;letter-spacing:0.05px;word-spacing:0.14px;}
#t1s_165{left:618px;bottom:754px;letter-spacing:0.13px;word-spacing:-1.18px;}
#t1t_165{left:875px;bottom:754px;}
#t1u_165{left:892px;bottom:754px;letter-spacing:0.16px;word-spacing:0.03px;}
#t1v_165{left:618px;bottom:731px;letter-spacing:0.04px;word-spacing:-0.34px;}
#t1w_165{left:618px;bottom:707px;letter-spacing:0.04px;}
#t1x_165{left:683px;bottom:715px;letter-spacing:-0.01px;}
#t1y_165{left:706px;bottom:707px;letter-spacing:0.2px;word-spacing:-0.02px;}
#t1z_165{left:618px;bottom:684px;letter-spacing:0.1px;word-spacing:0.08px;}
#t20_165{left:618px;bottom:661px;letter-spacing:0.03px;word-spacing:0.16px;}
#t21_165{left:986px;bottom:661px;letter-spacing:-0.35px;word-spacing:0.55px;}
#t22_165{left:1017px;bottom:661px;letter-spacing:0.27px;word-spacing:-0.08px;}
#t23_165{left:618px;bottom:638px;letter-spacing:-0.02px;word-spacing:0.22px;}
#t24_165{left:716px;bottom:638px;}
#t25_165{left:732px;bottom:638px;letter-spacing:0.06px;word-spacing:0.12px;}
#t26_165{left:618px;bottom:614px;letter-spacing:0.25px;word-spacing:-0.06px;}
#t27_165{left:618px;bottom:591px;letter-spacing:0.08px;word-spacing:-0.88px;}
#t28_165{left:618px;bottom:568px;letter-spacing:0.11px;word-spacing:0.08px;}
#t29_165{left:618px;bottom:545px;letter-spacing:0.06px;word-spacing:0.13px;}
#t2a_165{left:618px;bottom:522px;letter-spacing:0.08px;word-spacing:0.1px;}
#t2b_165{left:1029px;bottom:529px;letter-spacing:-0.01px;}
#t2c_165{left:1052px;bottom:522px;letter-spacing:-0.06px;}
#t2d_165{left:618px;bottom:498px;letter-spacing:0.12px;word-spacing:0.07px;}
#t2e_165{left:618px;bottom:475px;letter-spacing:0.06px;word-spacing:-0.95px;}
#t2f_165{left:1039px;bottom:475px;}
#t2g_165{left:1055px;bottom:475px;letter-spacing:-0.04px;word-spacing:0.23px;}
#t2h_165{left:618px;bottom:452px;letter-spacing:0.08px;word-spacing:-0.14px;}
#t2i_165{left:618px;bottom:430px;letter-spacing:0.11px;word-spacing:-0.47px;}
#t2j_165{left:618px;bottom:407px;letter-spacing:0.06px;word-spacing:0.12px;}
#t2k_165{left:618px;bottom:383px;letter-spacing:0.13px;word-spacing:0.06px;}
#t2l_165{left:908px;bottom:391px;letter-spacing:-0.01px;}
#t2m_165{left:931px;bottom:383px;letter-spacing:0.14px;word-spacing:0.04px;}
#t2n_165{left:618px;bottom:360px;letter-spacing:0.02px;word-spacing:-1.06px;}
#t2o_165{left:618px;bottom:337px;letter-spacing:0.16px;word-spacing:-0.5px;}
#t2p_165{left:1044px;bottom:345px;letter-spacing:-0.01px;}
#t2q_165{left:1067px;bottom:337px;letter-spacing:0.08px;word-spacing:0.11px;}
#t2r_165{left:618px;bottom:314px;letter-spacing:0.08px;word-spacing:0.1px;}
#t2s_165{left:618px;bottom:291px;letter-spacing:0.04px;word-spacing:0.15px;}
#t2t_165{left:618px;bottom:267px;letter-spacing:0.14px;word-spacing:0.05px;}
#t2u_165{left:1131px;bottom:267px;}
#t2v_165{left:1146px;bottom:267px;}
#t2w_165{left:618px;bottom:244px;letter-spacing:0.31px;}
#t2x_165{left:664px;bottom:252px;letter-spacing:-0.01px;}
#t2y_165{left:686px;bottom:244px;letter-spacing:0.14px;word-spacing:0.05px;}
#t2z_165{left:618px;bottom:221px;letter-spacing:0.09px;word-spacing:0.1px;}
#t30_165{left:618px;bottom:198px;letter-spacing:0.07px;word-spacing:0.11px;}
#t31_165{left:618px;bottom:174px;letter-spacing:0.17px;word-spacing:0.01px;}
#t32_165{left:618px;bottom:151px;letter-spacing:0.11px;word-spacing:0.08px;}
#t33_165{left:618px;bottom:128px;letter-spacing:0.13px;word-spacing:-1.17px;}
#t34_165{left:913px;bottom:128px;}
#t35_165{left:929px;bottom:128px;letter-spacing:0.2px;word-spacing:-0.01px;}
#t36_165{left:1162px;bottom:128px;}
#t37_165{left:618px;bottom:105px;letter-spacing:0.17px;word-spacing:-0.32px;}
#t38_165{left:1102px;bottom:105px;}
#t39_165{left:1118px;bottom:105px;letter-spacing:0.18px;}
#t3a_165{left:618px;bottom:82px;letter-spacing:0.06px;word-spacing:0.13px;}
#t3b_165{left:907px;bottom:89px;letter-spacing:-0.01px;}
#t3c_165{left:930px;bottom:82px;letter-spacing:0.1px;word-spacing:0.09px;}
#t3d_165{left:618px;bottom:58px;letter-spacing:0.06px;word-spacing:-0.8px;}
#t3e_165{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_165{font-size:10px;font-family:ArialMT_5tg;color:#000;}
.s1_165{font-size:6px;font-family:ArialMT_5tg;color:#000;}
.s2_165{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_165{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_165{font-size:17px;font-family:ArialMT_5tg;color:#000;}
.s5_165{font-size:11px;font-family:ArialMT_5tg;color:#000;}
.s6_165{font-size:17px;font-family:Arial-ItalicMT_kb;color:#000;}
.s7_165{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts165" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-ItalicMT_kb;
	src: url("fonts/Arial-ItalicMT_kb.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

</style>
<div id="pg165Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg165" style="-webkit-user-select: none;"><object width="1210" height="935" data="165/165.svg" type="image/svg+xml" id="pdf165" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_165" class="t s0_165">Version 4.2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_165" class="t s1_165">© </span>
<span id="t3_165" class="t s0_165">(NCCN </span>
<span id="t4_165" class="t s1_165">© </span>
<span id="t5_165" class="t s0_165">), All rights reserved. NCCN Guidelines </span>
<span id="t6_165" class="t s1_165">® </span>
<span id="t7_165" class="t s0_165">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_165" class="t s2_165">NCCN Guidelines Version 4.2024 </span>
<span id="t9_165" class="t s2_165">Head and Neck Cancers </span>
<span id="ta_165" class="t s3_165">MS-24 </span>
<span id="tb_165" class="t s4_165">support via feeding tubes). </span>
<span id="tc_165" class="t s5_165">324,325 </span>
<span id="td_165" class="t s4_165">Lymphedema of the head and neck </span>
<span id="te_165" class="t s4_165">commonly occurs in patients and is associated with increased symptom </span>
<span id="tf_165" class="t s4_165">burden (eg, negative cosmetic impact, trouble breathing, swallow </span>
<span id="tg_165" class="t s4_165">dysfunction, and pain). </span>
<span id="th_165" class="t s5_165">326-328 </span>
<span id="ti_165" class="t s4_165">Fibrosis can also occur. </span>
<span id="tj_165" class="t s5_165">329 </span>
<span id="tk_165" class="t s4_165">As lymphedema </span>
<span id="tl_165" class="t s4_165">and fibrosis negatively impact function and QOL, evaluation and </span>
<span id="tm_165" class="t s4_165">management is warranted. Patient referrals to occupational therapy to </span>
<span id="tn_165" class="t s4_165">learn massage techniques (eg, lymphatic decompression therapy) or to be </span>
<span id="to_165" class="t s4_165">fitted for custom-made compression devices may be warranted. Patients </span>
<span id="tp_165" class="t s4_165">are also at risk for problems with speech and/or swallowing. Treatment </span>
<span id="tq_165" class="t s4_165">and/or the progression of their disease may cause deterioration in their </span>
<span id="tr_165" class="t s4_165">ability to speak and/or swallow. </span>
<span id="ts_165" class="t s5_165">330-333 </span>
<span id="tt_165" class="t s4_165">Evaluation by a speech- </span>
<span id="tu_165" class="t s4_165">language/swallowing therapist is needed before and after treatment to </span>
<span id="tv_165" class="t s4_165">help mitigate potential problems. </span>
<span id="tw_165" class="t s5_165">334-336 </span>
<span id="tx_165" class="t s4_165">Patients are also at risk for dental </span>
<span id="ty_165" class="t s4_165">problems (see </span><span id="tz_165" class="t s6_165">Principles of Dental Evaluation and Management </span><span id="t10_165" class="t s4_165">in the </span>
<span id="t11_165" class="t s4_165">NCCN Guidelines for Head and Neck Cancers). Long-term swallowing and </span>
<span id="t12_165" class="t s4_165">dental dysfunction are particular risks that are worsened by multimodality </span>
<span id="t13_165" class="t s4_165">therapy and require long-term specialized attention. </span>
<span id="t14_165" class="t s4_165">Oral mucositis, or tissue damage, is common in patients treated with RT </span>
<span id="t15_165" class="t s4_165">for H&amp;N cancers, </span>
<span id="t16_165" class="t s5_165">337-342 </span>
<span id="t17_165" class="t s4_165">although use of advanced RT techniques (eg, </span>
<span id="t18_165" class="t s4_165">IMRT) may decrease the incidence and duration of this damage. </span>
<span id="t19_165" class="t s5_165">337,343,344 </span>
<span id="t1a_165" class="t s4_165">Oral mucositis causes pain in the mouth, which may affect the ability to eat </span>
<span id="t1b_165" class="t s4_165">and drink. </span>
<span id="t1c_165" class="t s5_165">337,340,341,345 </span>
<span id="t1d_165" class="t s4_165">Oral mucositis may be associated with breaks and/or </span>
<span id="t1e_165" class="t s4_165">delays in treatment, as well as hospitalization. </span>
<span id="t1f_165" class="t s5_165">338,339,341 </span>
<span id="t1g_165" class="t s4_165">Oral mucositis is </span>
<span id="t1h_165" class="t s4_165">more severe in patients receiving concurrent systemic therapy/RT. </span>
<span id="t1i_165" class="t s5_165">341 </span>
<span id="t1j_165" class="t s4_165">The </span>
<span id="t1k_165" class="t s4_165">Multinational Association of Supportive Care in Cancer and the </span>
<span id="t1l_165" class="t s4_165">International Society of Oral Oncology have published clinical practice </span>
<span id="t1m_165" class="t s4_165">guidelines for treatment of oral mucositis, although there are few high- </span>
<span id="t1n_165" class="t s4_165">quality studies in this area. </span>
<span id="t1o_165" class="t s5_165">346,347 </span>
<span id="t1p_165" class="t s4_165">Prevention and management of mucositis </span>
<span id="t1q_165" class="t s4_165">constitute an unmet medical need. </span>
<span id="t1r_165" class="t s4_165">In the randomized phase III Alliance A221304 trial, patients with H&amp;N </span>
<span id="t1s_165" class="t s4_165">cancer who were treated with RT ( </span><span id="t1t_165" class="t s6_165">N </span><span id="t1u_165" class="t s4_165">= 275) were randomized to receive a </span>
<span id="t1v_165" class="t s4_165">diphenhydramine-lidocaine-antacid mouthwash, doxepin mouthwash, or a </span>
<span id="t1w_165" class="t s4_165">placebo. </span>
<span id="t1x_165" class="t s5_165">348 </span>
<span id="t1y_165" class="t s4_165">The reduction in mucositis pain during the first 4 hours of </span>
<span id="t1z_165" class="t s4_165">treatment was significantly greater in the patients who received the </span>
<span id="t20_165" class="t s4_165">diphenhydramine-lidocaine-antacid mouthwash (</span><span id="t21_165" class="t s6_165">P = </span><span id="t22_165" class="t s4_165">.004) or the doxepin </span>
<span id="t23_165" class="t s4_165">mouthwash (</span><span id="t24_165" class="t s6_165">P </span><span id="t25_165" class="t s4_165">= .02), compared to the placebo. The practicality and </span>
<span id="t26_165" class="t s4_165">effectiveness of the doxepin-based regimen through an entire course of </span>
<span id="t27_165" class="t s4_165">RT is not established. Gabapentin is also under investigation for treatment </span>
<span id="t28_165" class="t s4_165">of pain from oral mucositis. In a prospective randomized pilot study, </span>
<span id="t29_165" class="t s4_165">patients with H&amp;N cancer who were treated with chemoradiation (N = 79) </span>
<span id="t2a_165" class="t s4_165">were randomized to receive gabapentin or usual care. </span>
<span id="t2b_165" class="t s5_165">349 </span>
<span id="t2c_165" class="t s4_165">Patients </span>
<span id="t2d_165" class="t s4_165">randomized to receive gabapentin reported a greater reduction in pain, </span>
<span id="t2e_165" class="t s4_165">compared to patients randomized to receive usual care ( </span><span id="t2f_165" class="t s6_165">P </span><span id="t2g_165" class="t s4_165">= .004). A small </span>
<span id="t2h_165" class="t s4_165">retrospective study including patients with H&amp;N cancer treated with RT or </span>
<span id="t2i_165" class="t s4_165">systemic therapy/RT showed that treatment with gabapentin for pain from </span>
<span id="t2j_165" class="t s4_165">oral mucositis is associated with a reduced need for narcotic pain </span>
<span id="t2k_165" class="t s4_165">medication and high doses of opioids. </span>
<span id="t2l_165" class="t s5_165">340 </span>
<span id="t2m_165" class="t s4_165">A single-institution study </span>
<span id="t2n_165" class="t s4_165">demonstrated that very-high-dose prophylactic gabapentin (2700 mg daily) </span>
<span id="t2o_165" class="t s4_165">also reduced the number of patients requiring narcotics. </span>
<span id="t2p_165" class="t s5_165">350 </span>
<span id="t2q_165" class="t s4_165">An unplanned </span>
<span id="t2r_165" class="t s4_165">secondary analysis of two consecutive prospective clinical trials showed </span>
<span id="t2s_165" class="t s4_165">that high-dose prophylactic gabapentin (3600 mg daily) was associated </span>
<span id="t2t_165" class="t s4_165">with greater time to first use of opioids, compared to 900 mg daily ( </span><span id="t2u_165" class="t s6_165">P </span><span id="t2v_165" class="t s4_165">&lt; </span>
<span id="t2w_165" class="t s4_165">.001). </span>
<span id="t2x_165" class="t s5_165">351 </span>
<span id="t2y_165" class="t s4_165">The toxicity of large dosages should not be underestimated and </span>
<span id="t2z_165" class="t s4_165">was not adequately explored in these studies. Larger scale studies are </span>
<span id="t30_165" class="t s4_165">awaited to fully assess the generalizability and toxicity of this dosing </span>
<span id="t31_165" class="t s4_165">schedule. In a randomized double-blind placebo-controlled study from </span>
<span id="t32_165" class="t s4_165">China (N = 128), patients with RT-related neuropathic pain who received </span>
<span id="t33_165" class="t s4_165">pregabalin reported greater pain relief ( </span><span id="t34_165" class="t s6_165">P </span><span id="t35_165" class="t s4_165">= .006 for 30% pain relief and </span><span id="t36_165" class="t s6_165">P </span>
<span id="t37_165" class="t s4_165">= .003 for 50% pain relief) and greater pain intensity reduction ( </span><span id="t38_165" class="t s6_165">P </span><span id="t39_165" class="t s4_165">= .003) </span>
<span id="t3a_165" class="t s4_165">than patients who received a placebo. </span>
<span id="t3b_165" class="t s5_165">352 </span>
<span id="t3c_165" class="t s4_165">The panel recommends </span>
<span id="t3d_165" class="t s4_165">consideration of doxepin, diphenhydramine-lidocaine-antacid mouthwash, </span>
<span id="t3e_165" class="t s7_165">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
